Top 50 Digital Therapeutics

NewPath develops digital therapeutics that deliver evidence-based behavioral health interventions through software. Their platform provides personalized, engaging programs to improve patient outcomes and expand access to mental healthcare.

Nunaps is a digital therapeutics startup focused on developing evidence-based interventions for mental health conditions through mobile applications. The platform provides users with personalized treatment plans and real-time progress tracking, enhancing accessibility to mental health care.

Click Therapeutics provides FDA‑cleared prescription digital therapeutics delivered through a HIPAA‑compliant mobile app that can be linked to a partner drug’s label to create a software‑enhanced therapy. The platform includes an adaptive neuromodulatory engine, real‑time analytics, and FHIR‑compatible EHR integration, allowing clinicians to monitor outcomes and pharmaceutical companies to augment their drug portfolios. Revenue is generated via product licensing, per‑patient subscription fees, and partnership milestone and royalty agreements.

Hippo TC develops digital therapeutics that employ evidence-based algorithms for diagnosing and treating depression, diabetes, and skin diseases. Their platform delivers personalized treatment plans and real-time monitoring, enhancing patient adherence and improving health outcomes.

Empower Therapeutics is a digital therapeutics company focused on delivering evidence-based interventions for chronic health conditions through mobile applications. Their platform provides personalized treatment plans that enhance patient engagement and adherence, ultimately improving health outcomes.

North Shore Therapeutics develops evidence-based digital therapeutics to address unmet treatment needs in serious mental illness. The company focuses on creating clinically validated software as a medical device (SaMD) solutions for psychiatry. Their pipeline includes augmented reality applications designed to improve patient engagement and therapeutic outcomes for conditions like schizophrenia.

Fitterfly provides personalized digital therapeutics programs for diabetes management and weight loss, utilizing continuous glucose monitoring and data-driven lifestyle interventions. Their approach combines expert guidance in nutrition, exercise, and mental wellness to help users achieve measurable health improvements, such as an average HbA1c reduction of 1.96% and weight loss of 5 kg.

Zeen Health is a digital therapeutics company that utilizes evidence-based cognitive behavioral therapy (CBT) techniques to provide accessible mental health services. The platform addresses the growing demand for effective mental health support by offering personalized treatment plans that improve user engagement and outcomes.

Newel Health develops AI-driven digital medical devices and Software as a Medical Device (SaMD) for chronic conditions like cardiometabolic disorders, neurological issues, and chronic pain. Their H.Core platform integrates regulatory compliance, behavioral science, and real-world data to rapidly build and scale clinical-grade software solutions. The company provides regulator-approved digital therapeutics that support sustained patient lifestyle change and continuous symptom management.

The startup develops artificial intelligence-driven digital therapeutics specifically designed for the management of neuropsychological disorders. Their technology enables healthcare professionals to enhance treatment efficacy and patient outcomes through tailored therapeutic interventions.

Prognoix develops evidence-based digital medicine solutions to address stigmatized health conditions. The company offers prescription digital therapeutics (DTx) like Melonga for premature ejaculation, providing discreet care access. Future pipeline products target metabolic syndrome and specific women's health issues.

Alex Therapeutics develops AI-integrated digital therapy companions that assist patients in managing complex treatment regimens and mental health challenges associated with cancer and rare diseases. Their evidence-based platform enhances patient adherence to medication and therapy, leading to improved health outcomes through behavior modification.

CureApp develops evidence-based therapeutic applications that provide personalized treatment interventions for conditions like hypertension outside traditional clinical settings. By utilizing digital therapy, the company enhances patient engagement and treatment efficacy, ensuring high-quality healthcare access for all.

Closed Loop Medicine develops personalized digital healthcare solutions that integrate dose-optimized drug therapy with digital therapeutics to enhance treatment adherence and patient outcomes. The platform addresses the inefficiencies of traditional healthcare delivery, which often leads to suboptimal management of chronic conditions and increased costs for payors.

Feel Therapeutics develops an AI-enabled Digital Precision Medicine Platform to objectively diagnose and manage mental health conditions. The platform continuously collects physiological and digital biomarker data from various sources to compute metrics related to mood, stress, and sleep. This objective data is then integrated into personalized Digital Therapeutic (DTx) and patient support programs for enhanced mental health outcomes.

Anthogen develops AI-powered digital therapeutics designed for the management of chronic illnesses directly on a patient's mobile device. The platform uses a proven health coach model, delivering personalized prevention and recovery programs through timely, in-the-moment prompts. This approach empowers individuals to make necessary behavioral adjustments, improving quality of life and reducing the strain on acute healthcare resources.

New Pill Technologies offers an AI-driven platform that utilizes data analytics to customize cannabis dosing and delivery based on individual patient profiles. This technology addresses the variability in patient responses to cannabis, enhancing therapeutic effectiveness and safety.

iQutis utilizes AI-driven digital therapeutics and mobile health applications to enhance treatment adherence for chronic skin conditions. By providing personalized skincare solutions and automated severity assessments, the platform improves patient outcomes and simplifies the management of skin health.

Sanara Health is developing digital therapeutics designed to manage chronic conditions through personalized, evidence-based interventions. The platform integrates patient data with clinical protocols to deliver scalable, remote care solutions. This approach aims to improve patient outcomes and reduce the burden on traditional healthcare systems.

Dawn Health develops regulated digital health products, including software as a medical device (SaMD) and digital therapeutics (DTx), to enhance chronic care management through patient empowerment and remote monitoring. Their platform accelerates the development and market entry of these solutions, improving patient adherence and outcomes while ensuring compliance with medical device regulations.

BehaVR develops immersive digital therapeutics for behavioral health using Virtual Reality technology to provide evidence-based treatment for mental health conditions. Their platform offers patients engaging therapeutic experiences that enhance treatment adherence and improve clinical outcomes.

Orange Therapeutics develops a multimodal AI system for precision medicine in chronic pain management. The platform integrates AI-driven diagnostics, personalized treatment solutions, and predictive analytics to anticipate pain episodes. This approach empowers patients and optimizes clinical decision-making for improved chronic pain outcomes.

Remepy develops Hybrid Drugs that combine pharmaceutical molecules with AI-driven digital protocols to improve clinical outcomes. These therapies integrate traditional medication with app-delivered digital interventions targeting motor, cognitive, and mental functions. The company leverages a Drug-SaMD combination pathway to validate and approve these novel, personalized treatment modalities.

This startup provides a SaaS platform for blended care, connecting healthcare professionals with patients to deliver and monitor remote mental health and chronic disease programs. The platform enables access to therapeutic resources and reduces stigmatization by facilitating remote care.

Neuroglee Therapeutics offers a digital therapeutic platform that provides personalized, multi-domain care plans and cognitive training for patients with mild cognitive impairment and dementia. By integrating a physician-led virtual care team and ongoing assessments, the platform enhances patient outcomes and supports caregivers in managing brain health from home.

MeditriX develops digital medical devices that integrate VR and biofeedback to improve mental wellness. Their Mindchair system uses physiological data like brainwaves and heart rate variability to provide real-time visual feedback, enabling users to actively regulate their stress and emotional responses.

eMotiv develops a mobile application that utilizes cognitive assessment through interactive games to evaluate mental health conditions, including ADHD. This platform provides users with accessible and engaging digital therapeutics aimed at enhancing cognitive function and improving overall mental well-being.

Caelum Health utilizes digital therapeutics to manage chronic digestive diseases through personalized treatment plans and real-time symptom tracking. This approach enhances patient adherence and improves health outcomes by providing targeted interventions based on individual data.

The startup offers a personalized digital therapy platform that provides expert-led courses, self-management tracking, and clinical messaging for patients with inflammatory conditions. This system enables clinicians and patients to monitor health progress and gain tailored insights, improving daily health outcomes and long-term management of chronic illnesses.

RespiGenes develops digital therapeutics and mobile health solutions for respiratory and cardiovascular diseases. They partner with pharmaceutical and biopharmaceutical companies to support clinical research and improve patient outcomes through technology.

The startup has developed a digital therapy application that provides cancer patients with tailored information on diagnosis, treatment options, nutritional guidance, and relaxation techniques. This application supports patients in managing the complexities of their illness and enhances their overall well-being through accessible digital resources.

GluCare.Health provides a hybrid care model for diabetes and endocrine disorders, integrating continuous remote data monitoring with a multidisciplinary clinical team. The platform uses AI-powered diagnostics and digital therapeutics to deliver personalized, data-driven treatment plans and proactive patient engagement for improved metabolic health.

NowPatient Diabetes is a digital therapeutics application that enables personalized diabetes self-management through real-time health data tracking and tailored health insights. The platform provides users with actionable recommendations based on their individual health metrics, facilitating better control of their diabetes.

Affect Therapeutics offers a smartphone app that integrates contingency management with virtual therapy to support individuals recovering from drug and alcohol addiction. The platform provides financial incentives for healthy behaviors, along with personalized care and resources to facilitate lasting lifestyle changes.

Nerveli provides a science-based mobile application designed to simplify pain recovery through personalized tools and educational resources. The platform helps users understand their pain patterns and build self-management skills outside of clinical settings. This digital therapeutic supports patients while offering providers and payors better patient context and reduced downstream care costs.

Amara Therapeutics is a digital therapeutic platform that offers personalized health tracking and educational resources for women with pelvic floor disorders. The platform provides evidence-based interventions to improve symptom management and enhance access to tailored support for pelvic health issues.

Aureka Biotechnologies uses integrated digital biology and generative AI to accelerate the discovery of high-value protein therapeutics. Their platform enables rapid "Generate-Test-Learn-Optimize" cycles, significantly increasing discovery efficiency for immunotherapies. This approach aims to deliver better drugs faster and at a lower cost for challenging disease targets.

KStrategy& provides strategic planning and decision-support tools for the bio/pharma sector, offering early Budget Impact Analysis (BIA) insights to enhance commercial viability. The company also offers LaunchEdge, an AI-driven platform for market intelligence and launch planning specifically for the Digital Therapeutics (DTx) space. These products help manufacturers make informed decisions throughout drug development and navigate the evolving digital health landscape.

The startup offers online therapy courses that utilize psychologically guided methods to provide anonymous and flexible treatment for individuals experiencing psychological stress and mental health disorders. By delivering structured programs, the company enables users to effectively manage symptoms of depression and other mental health issues.

Sharecare provides a HIPAA‑compliant digital health platform that aggregates medical records, claims, and wearable data into a single profile and offers AI‑driven analytics, virtual AskMD consults with board‑certified clinicians, and a searchable provider directory. The platform also includes a benefits hub, a digital therapeutics library, and FHIR‑compatible APIs for integration with employers, health plans, and public‑sector programs to improve member engagement and lower care costs.

NeuroAge Therapeutics provides comprehensive AI-powered cognitive testing that integrates online assessments, blood biomarkers, genetics, and MRI data. This analysis determines an individual's brain aging rate to assess future risk for neurodegenerative diseases like Alzheimer's and Parkinson's. The company then delivers personalized recommendations aimed at slowing brain aging and developing tailored therapeutics for neurodegeneration.

The startup offers a digital health platform that connects patients with a network of mental health professionals to deliver personalized, evidence-based mental health programs and therapies. This system provides users with tailored self-help resources and consultations, addressing the need for accessible and individualized mental health support.

The startup has developed a healthcare technology platform that utilizes virtualized therapy management and adaptive machine learning to enhance the delivery of care by specialists. This platform enables clinicians to effectively interpret clinical evidence and respond to the physiological impacts of diseases and therapies, bridging the gap between medical knowledge and patient experiences.

Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases by decoding complex biology into actionable insights. The company utilizes its Mirador360™ engine, which integrates biology, multi-modal data, and AI, to identify novel targets and optimal combination therapies. This approach accelerates the pipeline of potentially transformational therapies aimed at improving patient outcomes in I&I conditions.

The startup has developed a digital therapeutic platform that utilizes artificial intelligence and offline speaker services to enhance cognitive function in individuals with cognitive impairment. This technology provides medical professionals with software-based cognitive training regimens and diagnostic tools specifically designed for dementia treatment.

The startup develops digital therapeutics and health applications that provide targeted treatment methods for complex diseases such as ophthalmology, neuropsychiatry, cancer, and immunology. By leveraging therapeutic devices and technologies, the company addresses the unmet medical needs of patients who struggle to find effective treatments with existing medical solutions.

The startup offers a digital sexual therapy application that utilizes algorithm-driven assessments to identify sexual dysfunction and create personalized treatment plans. This platform enables users to engage in therapy independently, making sexual health support affordable and accessible without the stigma often associated with traditional therapy.

The startup offers a suite of mental healthcare applications that utilize evidence-based therapeutic techniques, such as cognitive behavioral therapy (CBT) and mindfulness practices, to support users in managing anxiety and depression. By providing personalized progress tracking and real-time feedback, the platform enhances user engagement and improves mental health outcomes.

Psyber develops brain-computer interface (BCI)-enabled digital therapeutics to create targeted interventions for mental health disorders. Their technology aims to facilitate behavioral changes by providing measurable improvements in mental well-being through personalized therapeutic experiences.

Blue Note Therapeutics develops prescription digital therapeutics that utilize evidence-based behavioral interventions to improve patient outcomes in mental health. The company targets the challenges of treatment adherence and access to care by providing scalable, clinically validated solutions for patients managing mental health conditions.